Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy
Conditions
Interventions
Computed Tomography
Copanlisib Hydrochloride
+5 more
Locations
5
United States
University of Colorado Hospital
Aurora, Colorado, United States
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Women and Infants Hospital
Providence, Rhode Island, United States
Start Date
June 30, 2022
Primary Completion Date
March 17, 2023
Completion Date
March 17, 2023
Last Updated
September 26, 2023
NCT05271318
NCT04739800
NCT04678102
NCT02835833
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions